Cytokinetics, Incorporated
CYTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating. The company carries a $8.51B market cap, placing it firmly in the mid-cap category. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Market Cap
$8.51B
Beta
0.41
P/E (TTM)
—
P/E (Fwd)
-13.91
EPS (TTM)
$-7.22
EPS (Fwd)
$-4.40
ROE
—
ROA
-28.1%
Cash
$1.17B
Total Debt
$1.42B
Free CF
-$397.4M
52W Change
1.7%
Annual Financials
Cash vs Debt
Where CYTK stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, CYTK finished 11.49% below its 150-day moving average ($72.22) and 8.85% below its 200-day moving average ($70.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CYTK overbought or oversold?
At the October 16, 2026 close, CYTK's RSI(14) was 47.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CYTK has $1.17B in cash with $1.42B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$397.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $94.6M (2022) to $88.0M (2025).
With a beta below 0.7, Cytokinetics, Incorporated typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cytokinetics, Incorporated and its sector.